San Francisco
Joined June 2013
- Tweets29.3K
- Following3.4K
- Followers1.8K
- Likes36.3K
Pinned Tweet
An honor to contribute to developing new PrEP options and providing new choices for people disproportionately affected by HIV and historically underrepresented in PrEP studies. #aids2022 #prep #communityengagement
Moupali Das, MD, MPH retweeted
#GileadNews: We’ve expanded the scope of our six royalty-free voluntary licensing agreements for our twice-yearly HIV prevention medicine to include an investigational once-yearly formulation. Read more: gilead.inc/4AhPLMT
Moupali Das, MD, MPH retweeted
#GileadNews: This milestone reflects our commitment to engaging with global stakeholders, including partners like PAHO, to help countries move quickly from scientific innovation to real-world access to HIV prevention. Read more: gilead.inc/4dBBSiI
Moupali Das, MD, MPH retweeted
#GileadNews: At #AIDS2026, in collaboration with @Merck, we’re presenting new data from our Phase 3 trials evaluating an investigational long-acting oral treatment for adults with virologically suppressed HIV.
Read the full press release here: gilead.inc/3TfiSiP
Moupali Das, MD, MPH retweeted
#GileadNews: The U.S. FDA has accepted our filing for our investigational once-weekly oral option for the prevention of HIV as pre-exposure prophylaxis (PrEP). If approved, this formulation could be the first once-weekly oral PrEP option. Read more: gilead.inc/4oxl5BJ
Moupali Das, MD, MPH retweeted
#GileadNews: We are donating antiviral medication to the Government of Uganda to support Ebola response efforts.
Additional supplies are being readied to support the regional outbreak response. gilead.inc/4ekgtKD
Moupali Das, MD, MPH retweeted
Science has transformed the fight against HIV/AIDS, but there’s more work ahead. Today, the National AIDS Memorial and the Gilead Foundation announced a 3-year, nearly $3M commitment to preserve HIV history and support future community leaders. Learn more: gilead.inc/4v7D3xk
Moupali Das, MD, MPH retweeted
#GileadNews: Today, in collaboration with @Merck, we announced positive topline results from a Phase 3 study evaluating an investigational long-acting oral HIV treatment. Read the full press release here: gilead.inc/4xfl21p
Moupali Das, MD, MPH retweeted
Because of the leadership of the @GovernmentZA and the @GlobalFund, access to long-acting HIV prevention medication is accelerating. This effort underscores the power of global partnership to help drive progress toward ending HIV as a public health threat. gilead.inc/4atLiv4
Moupali Das, MD, MPH retweeted
#GileadNews: Gilead joined partners in delivering the first shipments of our twice-yearly HIV prevention option to Eswatini & Zambia, an important milestone in our shared efforts to accelerate progress toward ending the HIV epidemic in sub-Saharan Africa. gilead.inc/47NB7AW
Moupali Das, MD, MPH retweeted
During the Q&A, @drmoupali and Dr. @CharlesBHolmes addressed audience questions ranging from how lessons learned from COVID-19 informed Gilead’s approach to lenacapavir, to how the PURPOSE program is navigating cultural barriers to treatment access.
Moupali Das, MD, MPH retweeted
.@drmoupali speaks on inclusive efforts to make sure the Purpose programs represented and benefited the most disproportionately impacted communities.
Moupali Das, MD, MPH retweeted
The CDC officially recommends Yeztugo (lenacapavir), @GileadSciences' long-acting injectable form of pre-exposure prophylaxis, or PrEP, for people at risk of HIV. In clinical trials, the injection, given every six months, all but eliminated new cases of HIV.
"Lenacapavir, administered as subcutaneous injections every 6 months, is recommended as an HIV PrEP option in persons weighing ≥77 lbs (≥35 kg) who would benefit from PrEP. This is a strong recommendation, based on high certainty of evidence."
Moupali Das, MD, MPH retweeted
#GileadNews: @CDCgov has released new guidelines for our twice-yearly #HIV prevention medication. This is an important milestone as we strive to help transform HIV prevention in the U.S. More: gilead.inc/4pAcKxu
Moupali Das, MD, MPH retweeted
5/ That inclusion was no accident.
Dr. Moupali Das, head of HIV prevention at Gilead, led the trial with a focus on equity—centering women from the start, not as an afterthought.
Moupali Das, MD, MPH retweeted
Lenacapavir was recently approved by the FDA, marking a milestone in the decades-long fight to end the HIV epidemic. Three individual who were instrumental in developing the drug were honored last month with the AAAS Mani L. Bhaumik Breakthrough of the Year Award.
Moupali Das, MD, MPH retweeted
#GileadNews: The FDA has approved our injectable HIV-1 prevention medication, making it the first and only twice-yearly #HIV prevention option in the U.S. This approval is helping to usher in the future of prevention as we work to help end the epidemic. gilead.inc/4e9KI6B
Moupali Das, MD, MPH retweeted
This annual shot might protect against HIV infections trib.al/jDdxIF1
Moupali Das, MD, MPH retweeted
ICYMI: Dr. @drmoupali presented data at #CROI2025 showing @GileadSciences's once-yearly Lenacapavir formulations for HIV PrEP sustain efficacy for 56 weeks. The phase 1 study paves the way for improved adherence & HIV prevention @CROI_Official @TheLancet
contagionlive.com/view/gilea…
Moupali Das, MD, MPH retweeted
#GileadNews: Today at #CROI2025, we announced initial data about our investigational once-yearly medication for HIV prevention. This is part of our mission to continue to innovate new person-centered #HIV prevention options. Learn more: gilead.inc/3FlRjNP